Bliss GVS Pharma's Q1 FY 2026-27 Quarterly Results
- 13 Aug 2026
Result Summary
- Bliss GVS Pharma Ltd reported a 10.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 21.5%.
- Its expenses for the quarter were down by 1.6% QoQ and up 22.2% YoY.
- The net profit increased 38.8% QoQ and increased 15.8% YoY.
- The earnings per share (EPS) of Bliss GVS Pharma Ltd stood at 4.65 during Q1 FY 2026-27.
Financial Statments for Q1 FY 2026-27
(₹ crores) | Q1FY27 | Q4FY26 | Q1FY26 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 295.18 | 268.15 | 242.92 | 10.1% | 21.5% |
Total Expenses | 219.70 | 223.23 | 179.81 | -1.6% | 22.2% |
Profit Before Tax | 75.48 | 44.95 | 63.11 | 67.9% | 19.6% |
Tax | 24.11 | 7.95 | 18.75 | 203.3% | 28.6% |
Profit After Tax | 51.37 | 37.00 | 44.36 | 38.8% | 15.8% |
Earnings Per Share | 4.65 | 3.28 | 4.04 | 41.8% | 15.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Bliss GVS Pharma Ltd is a pharmaceutical company that primarily operates in the healthcare and pharmaceutical sector. The company is involved in the manufacturing and marketing of pharmaceutical formulations and bulk drugs. Bliss GVS Pharma Ltd focuses on a wide range of therapeutic areas, including gynecology, anti-malarial, and dermatology, among others. The company has a global presence, with a significant portion of its revenue coming from international markets. As of the latest updates available, there are no specific recent major developments provided in the data.
Revenue
In the first quarter of FY27, Bliss GVS Pharma Ltd reported a total income of ₹295.18 crores. This represents a 10.1% increase from the previous quarter (Q4FY26), where the total income was ₹268.15 crores. Year-over-year, the total income increased by 21.5%, compared to ₹242.92 crores in Q1FY26. This growth in revenue indicates an upward trajectory in the company's income generation over both the quarter and the year. Such growth trends in revenue can be significant for assessing the company's market performance and operational expansion over time.
Profitability
For the first quarter of FY27, Bliss GVS Pharma Ltd's profit before tax stood at ₹75.48 crores, marking a substantial quarter-over-quarter increase of 67.9% from ₹44.95 crores in Q4FY26. Year-over-year, there was a 19.6% rise from ₹63.11 crores in Q1FY26. The profit after tax for Q1FY27 was ₹51.37 crores, which also saw a significant quarter-over-quarter growth of 38.8% from ₹37.00 crores in Q4FY26, and a year-over-year increase of 15.8% from ₹44.36 crores in Q1FY26. Earnings per share for Q1FY27 increased to ₹4.65 from ₹3.28 in Q4FY26 and ₹4.04 in Q1FY26, reflecting a 41.8% QoQ growth and a 15.1% YoY growth. These metrics highlight a positive shift in the company's profitability metrics during the analyzed periods.
Operating Metrics
The operational expenses for Bliss GVS Pharma Ltd in Q1FY27 were recorded at ₹219.70 crores, showing a decrease of 1.6% from ₹223.23 crores in Q4FY26. However, compared to the same quarter in the previous year, there was an increase of 22.2% from ₹179.81 crores in Q1FY26. The tax expenses for the first quarter of FY27 were ₹24.11 crores, with a significant quarter-over-quarter increase of 203.3% from ₹7.95 crores in Q4FY26, and a year-over-year increase of 28.6% from ₹18.75 crores in Q1FY26. These operating metrics provide insight into the company's cost management and tax obligations during the reporting period.
FAQs
Bliss GVS Pharma Ltd announced its Q1 FY 2026-27 results on 13 August, 2026.
Bliss GVS Pharma Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of Bliss GVS Pharma Ltd Q1 FY 2026-27 results include:
- Revenue: ₹295.18 crore
- Net Profit: ₹51.37 crore
- EBITDA: ₹86.00 crore
- Year-over-Year Growth: 21.5%
- Quarter-over-Quarter Growth: 10.1%
Bliss GVS Pharma Ltd reported a net profit of ₹51.37 crore in Q1 FY 2026-27, reflecting a 15.8% year-over-year growth.
Bliss GVS Pharma Ltd posted a revenue of ₹295.18 crore in Q1 FY 2026-27.